Introduction

35
Intestinal intraepithelial lymphocytes (IEL) constitute a population of cells dwelling (Fig. 1b) . Moreover, the IEL compartment of E8 I -/-Rag-2 -/-mice also presented a 162 significant reduction in the frequencies and cell numbers of NKp46 + NK1.1 + IEL (Fig. 1b) . These 163 cells do not express CD8 homodimers (Fig. 1a , right dot plots) and therefore the decrease in 164 numbers is not directly related with the E8 I mutation. 169 have been reported to be a source of osteopontin, we reasoned that the significant absence of 170 these cells in E8 I -/-Rag-2 -/-mice may result in decrease osteopontin production in the intestines.
171 Indeed, the expression of osteopontin mRNA in the intestines of Rag-2 -/-mice was significantly 172 higher than that observed in the intestines of E8 I -/-Rag-2 -/-mice ( Fig. 2a) (Fig. 6a ) and presented less colon pathology 238 (Fig. 6b) , mirroring the observed results in Spp-1 -/-Rag-2 -/-mice (Fig. 5a) . Analysis of the 239 kinetics of osteopontin expression in the colon of anti-CD40-treated Rag-2 -/-and E8 I -/-Rag-2 -/-240 mice showed incremental expression of osteopontin mRNA at day 2 and 7 post disease 241 induction; however, the levels of osteopontin mRNA levels were consistently lower in E8 I -/-Rag-242 2 -/-mice than in Rag-2 -/-mice (Fig. 6c) . To investigate whether treatment with osteopontin 243 increases disease severity in iCD8 cell-deficient mice, E8 I -/-Rag-2 -/-mice were injected i.p. at 244 day -2, -1, and 0 with recombinant osteopontin, followed by disease induction with a reduced 245 dose of anti-CD40 at day 0 (a lower dose was chosen to better detect changes in disease 246 severity). Rag-2 -/-control mice lost similar weight with low anti-CD40 than mice treated with the 247 regular dose (compare Fig. 6a and 6d) ; however, E8 I -/-Rag-2 -/-mice treated with low anti-CD40
248 recovered faster than E8 I -/-Rag-2 -/-mice treated with the full anti-CD40 dose (compare Fig. 6a 249 and 6d). Although, E8 I -/-Rag-2 -/-mice treated with recombinant osteopontin presented weight 250 loss similar to PBS-treated E8 I -/-Rag-2 -/-mice during the first few days after disease induction, 251 the former group did not recover as the PBS-treated group and their weights were more similar to 252 Rag-2 -/-control mice. (Fig. 6d) . Although colon pathological scores were comparable between 253 the control and recombinant osteopontin-treated E8 I -/-Rag-2 -/-groups, there was a tendency for 254 higher disease severity in the latter group. Therefore, our results indicate that administration of 255 osteopontin slightly increases disease severity in the absence of iCD8 cells and low osteopontin 256 expression in the colon. 
305
Our in vivo evidence presented in this report indicates that iCD8 cells represent one of 306 the innate IEL populations with highest levels of osteopontin expression, and that mice deficient 307 in iCD8 cells also present decreased osteopontin levels in the colon (Fig. 2a) 
335
In conclusion, in this report we provide evidence indicating an important and novel role 336 for iCD8 cells in the homeostasis of NKp46 + NK1.1 + IEL. We also show that the effect of 337 iCD8 cells is mediated in part by osteopontin, which adds to the growing roles of this cytokine 338 in different biological processes. 
